Document text
Principal Investigator: Kyuyeon Han
Organization: UNIVERSITY OF ILLINOIS AT CHICAGO
Fiscal Year: 2024
Award: $239,850
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary/Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could behave similar to the influenza virus, re-
emerging every year in slightly different forms. More importantly, SARS-CoV-2 keeps making various mutants
with higher infection rates than previous ones. The spike protein (S) of SARS-CoV-2 binds to host angiotensin-
converting enzyme 2 (ACE2) protein to mediate viral entry. The replication of SARS-CoV-2 depends on two
essential viral proteases: 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro). The goal of
this application is to selectively target 3CLpro to inhibit virus replication. We plan to develop the host matrix
metalloproteinase 14 (MMP14) as a degrader of SARS-CoV-2 3CLpro to specifically inhibit replication of SARS-
CoV-2. The MMP14 is important for various cellular process through its proteolytic activity. We demonstrated
that MMP14 directly binds and selectively cleaves the viral 3CLpro at multiple locations. Consequently, replication
of SARS-CoV-2 Pseudovirus was inhibited by overexpression of active MMP14 in HEK293T cells. We have
engineered a novel inactive form of MMP14 (pro-PL-MMP14) containing viral PLpro cleavage site between pro-
domain and active MMP14 to increase target specificity for SARS-CoV-2. Thus, only SARS-CoV-2 PLpro can
release pro-domain to convert inactive to active form of MMP14. Furthermore, our results show that MMP14 is
enriched in isolated exosomes. Corneal mesenchymal stem cell-derived exosomes have been suggested as a
new strategy to deliver therapeutic agents. Here we propose to use the engineered pro-PL-MMP14, which can
be delivered by the pro-PL-MMP14/hACE2 or pro-PL-MMP14/DX600-laden exosomes, to specifically degrade
the viral 3CLpro, in the infected and susceptible cells, leading to inhibition of SARS-CoV-2 replication, as a novel
therapeutic agent. We propose two specific aims: (1) Characterize the engineered pro-PL-MMP14 and its ability
to inhibit SARS-CoV-2 replication; (2) Develop advanced pro-PL-MMP14-laden exosomes for specific delivery.
We will complete these aims using innovative techniques from molecular biology, biophysics, and molecular
virology.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><ACE2><Anti-viral Agents><BSL-3 facility><BSL3 facility><Binding><Biochemistry><Biological Chemistry><Biophysics><Buccal Cavity><Buccal Cavity Head and Neck><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 virus><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cavitas Oris><Cell Body><Cell Function><Cell Physiology><Cell Process><Cell-Extracellular Matrix><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chymase><Clinical><CoV-2><CoV2><Cornea><Coughing><DNA Molecular Biology><Development><Disinfectants><Drug Targeting><ECM><Engineering><Esteroproteases><Exhibits><Extracellular Matrix><Eye><Eyeball><Family><Goals><Hand><In Vitro><Influenza Virus><Kinetics><Location><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><MMCP-1><MMP14><MMP14 gene><MMPs><MT1-MMP><Masks><Matrix Metalloproteinase-14><Matrix Metalloproteinases><Mediating><Membrane-Type Matrix Metalloproteinase 1><Membrane-Type Matrix Metalloproteinase 14><Mesenchymal Progenitor Cell><Mesenchymal Stem Cells><Mesenchymal progenitor><Mesenchymal stromal/stem cells><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle East Respiratory Virus><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Molecular Biology><Molecular Biology Techniques><Molecular Interaction><Molecular Virology><Mouth><Nasal><Nasal Passages Nose><Non-structural Protein><Nonstructural Protein><Nose><Oral cavity><Papain><Peptidases><Peptide Hydrolases><Peptides><Persons><Polyproteins><Predisposition><Process><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Public Health><Reporting><Research><Respiratory System, Nose, Nasal Passages><SARS Coronavirus 2 Protease><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 protease><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Specificity><Subcellular Process><Surface><Susceptibility><Techniques><Testing><Therapeutic><Therapeutic Agents><Transmission><Vero Cells><Viral><Virus><Virus Replication><Work><Wound Repair><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral development><antiviral drug development><antiviral therapeutic development><antiviral therapy development><assess effectiveness><biophysical foundation><biophysical principles><biophysical sciences><biosafety level 3 facility><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><chymase-1><chymotrypsin-like protease><combat><corneal><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><current pandemic><determine effectiveness><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><effectiveness assessment><effectiveness evaluation><engineered exosomes><evaluate effectiveness><examine effectiveness><exosome><experience><experiment><experimental research><experimental study><experiments><hCoV19><hands><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><influenzavirus><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><mast cell protease><mast cell protease 1><mast cell protease I><mast cell proteinase-1><member><mesenchymal stromal progenitor cells><mesenchymal-derived stem cells><mutant><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><overexpress><overexpression><particle><present pandemic><rate of infection><respiratory><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 protease><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><skeletal muscle protease><spike proteins on SARS-CoV-2><stem cell derived exosomes><stem cell exosomes><therapeutics against COVID-19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><transmission process><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><viral multiplication><viral replication><virology><virus multiplication><wound healing><wound recovery><wound resolution>